Replies to post #3842 on GTC Biotherapeutics (fka GTCB)

[ThomasS]

Unless the following excerpts are meant to include psoriasis:

"...and an exploratory, dose-ranging Phase 2 study."

"Its lead compound, MM-093, is currently in clinical development to treat patients with rheumatoid arthritis, psoriasis or with autoimmune uveitis."

[mblimon]

Apart from the phrase at the end where psoriasis is still mentioned as being in clinical development (see ThomasS), there is also another phrase where psoriasis is still mentioned.

"We continue to view MM-093 as a novel and highly differentiated therapeutic that could have a significant impact in the treatment of autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, uveitis, inflammatory bowel disease and psoriasis, among others."

True, it is remarkable, that psoriasis is missing where you indicated. But it is not enough to write it off IMO.

[gfp927z]

Dew, Since GTCB now has the broad US patent for the production of any therapeutic protein in the milk of any transgenic animal (through 2021), will potential competitors like Pharming and Avigenics first have to obtain a license from GTCB prior to commercializing any of their transgenic products? Do you know if GTCB has a similar patent in Europe, or one pending? Thanks.